---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-202617"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2022-07-27T23:59:59+00:00"
generated_at: "2026-06-24T08:07:41.754139+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Apellis exchanges $75.6M of convertible notes for common stock shares

## Summary
- Exchanged ~$65.9M principal for 2,036,886 shares; ~$9.7M for 195,809 shares plus additional based on VWAP.
- Transactions expected to close August 1, 2022, subject to customary closing conditions.
- Shares issued to QIBs and institutional accredited investors under Section 4(a)(2) exemption.
- Debt reduction strengthens balance sheet but dilutes existing shareholders by ~2.2M shares.

## SEC filing metadata
- accession: 0001193125-22-202617
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2022-07-27T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312522202617/0001193125-22-202617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312522202617/d338727d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-202617
- JSON: https://secwatch.observer/filing/0001193125-22-202617.json
- Plain text: https://secwatch.observer/filing/0001193125-22-202617.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.